Can resectability conversion in patients with metastatic colon-rectal cancer to liver improve survival?

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter A. El-Nagar
Citation Annals of Oncology (2016) 27 (2): 86-101. 10.1093/annonc/mdw201
Authors A. El-Nagar, M. Mohamed, W. Mansy, L. Abdelaziz
  • Faculty of Medicine, Zagazig University, Zagazig, Egypt, /


Background: Colon-rectal cancer is the fourth most frequent cancer worldwide, unfortunately 35%–50% develop metastasis, 60%–80% of them have unresectable liver metastasis, 20% to 34% present with synchronous liver metastasis, only 15%–20% will be candidate for hepatectomy, While chemotherapy can convert around 10% to resectability, R0 surgical resection leads to improvement in median 5-years survival in patients with resected liver metastasis. Aim: To study the efficacy of FOLFOX6 in conversion of unresectable colo-rectal cancer with liver limited metastasis to resectability and the effect of resection on overall survival.